Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
dc.contributor.author | Sharkey, Mark E. | |
dc.contributor.author | Teo, Ian | |
dc.contributor.author | Greenough, Thomas | |
dc.contributor.author | Sharova, Natalia | |
dc.contributor.author | Luzuriaga, Katherine | |
dc.contributor.author | Sullivan, John L. | |
dc.contributor.author | Bucy, R. Pat | |
dc.contributor.author | Kostrikis, Leondios G. | |
dc.contributor.author | Haase, Ashley | |
dc.contributor.author | Veryard, Claire | |
dc.contributor.author | Davaro, Raul E. | |
dc.contributor.author | Cheeseman, Sarah H. | |
dc.contributor.author | Daly, Jennifer S. | |
dc.contributor.author | Bova, Carol A | |
dc.contributor.author | Ellison, Richard T. III | |
dc.contributor.author | Mady, Brian | |
dc.contributor.author | Lai, Kwan Kew | |
dc.contributor.author | Moyle, Graeme | |
dc.contributor.author | Nelson, Mark | |
dc.contributor.author | Gazzard, Brian | |
dc.contributor.author | Shaunak, Sunil | |
dc.contributor.author | Stevenson, Mario | |
dc.date | 2022-08-11T08:09:05.000 | |
dc.date.accessioned | 2022-08-23T16:17:24Z | |
dc.date.available | 2022-08-23T16:17:24Z | |
dc.date.issued | 2000-01-01 | |
dc.date.submitted | 2008-06-16 | |
dc.identifier.citation | Nat Med. 2000 Jan;6(1):76-81. <a href="http://dx.doi.org/10.1038/71569">Link to article on publisher's site</a> | |
dc.identifier.issn | 1078-8956 (Print) | |
dc.identifier.doi | 10.1038/71569 | |
dc.identifier.pmid | 10613828 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/34559 | |
dc.description.abstract | Treatment of HIV-1-infected individuals with a combination of anti-retroviral agents results in sustained suppression of HIV-1 replication, as evidenced by a reduction in plasma viral RNA to levels below the limit of detection of available assays. However, even in patients whose plasma viral RNA levels have been suppressed to below detectable levels for up to 30 months, replication-competent virus can routinely be recovered from patient peripheral blood mononuclear cells and from semen. A reservoir of latently infected cells established early in infection may be involved in the maintenance of viral persistence despite highly active anti-retroviral therapy. However, whether virus replication persists in such patients is unknown. HIV-1 cDNA episomes are labile products of virus infection and indicative of recent infection events. Using episome-specific PCR, we demonstrate here ongoing virus replication in a large percentage of infected individuals on highly active anti-retroviral therapy, despite sustained undetectable levels of plasma viral RNA. The presence of a reservoir of 'covert' virus replication in patients on highly active anti-retroviral therapy has important implications for the clinical management of HIV-1-infected individuals and for the development of virus eradication strategies. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10613828&dopt=Abstract ">Link to article in PubMed</a> | |
dc.relation.url | http://dx.doi.org/10.1038/71569 | |
dc.subject | Anti-HIV Agents | |
dc.subject | Base Sequence | |
dc.subject | CD4 Lymphocyte Count | |
dc.subject | DNA Primers | |
dc.subject | Drug Therapy, Combination | |
dc.subject | HIV Infections | |
dc.subject | *HIV Long Terminal Repeat | |
dc.subject | HIV-1 | |
dc.subject | Humans | |
dc.subject | Lymphocytes | |
dc.subject | RNA, Viral | |
dc.subject | Reference Values | |
dc.subject | Reverse Transcriptase Inhibitors | |
dc.subject | Viral Load | |
dc.subject | Virus Replication | |
dc.subject | Immunology of Infectious Disease | |
dc.subject | Immunoprophylaxis and Therapy | |
dc.subject | Virus Diseases | |
dc.title | Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy | |
dc.type | Journal Article | |
dc.source.journaltitle | Nature medicine | |
dc.source.volume | 6 | |
dc.source.issue | 1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/gsn_pp/7 | |
dc.identifier.contextkey | 530690 | |
html.description.abstract | <p>Treatment of HIV-1-infected individuals with a combination of anti-retroviral agents results in sustained suppression of HIV-1 replication, as evidenced by a reduction in plasma viral RNA to levels below the limit of detection of available assays. However, even in patients whose plasma viral RNA levels have been suppressed to below detectable levels for up to 30 months, replication-competent virus can routinely be recovered from patient peripheral blood mononuclear cells and from semen. A reservoir of latently infected cells established early in infection may be involved in the maintenance of viral persistence despite highly active anti-retroviral therapy. However, whether virus replication persists in such patients is unknown. HIV-1 cDNA episomes are labile products of virus infection and indicative of recent infection events. Using episome-specific PCR, we demonstrate here ongoing virus replication in a large percentage of infected individuals on highly active anti-retroviral therapy, despite sustained undetectable levels of plasma viral RNA. The presence of a reservoir of 'covert' virus replication in patients on highly active anti-retroviral therapy has important implications for the clinical management of HIV-1-infected individuals and for the development of virus eradication strategies.</p> | |
dc.identifier.submissionpath | gsn_pp/7 | |
dc.contributor.department | Program in Molecular Medicine | |
dc.contributor.department | Department of Medicine, Division of Infectious Diseases and Immunology | |
dc.contributor.department | Department of Pediatrics | |
dc.contributor.department | Office of Research | |
dc.contributor.department | Center for Infectious Disease and Vaccine Research | |
dc.contributor.department | Graduate School of Nursing | |
dc.source.pages | 76-81 |